REG4 and colonic neoplasm: Inhibitors targeting some cathepsins, such as S and K, are already in clinical evaluation [70], and inhibition of the Reg4-CD44/CD44ICD pathway has been proposed as a future therapeutic target for colon cancer patients [71].